The global market for barrett’s esophagus with dysplasia treatment is poised for significant growth, with a projected valuation of USD 4.5 million in 2023, escalating to an impressive USD 7.54 million by 2033. This remarkable expansion represents a compound annual growth rate (CAGR) of 5.3% during the forecast period from 2023 to 2033.
The upward trend in market performance follows a steady historical growth trajectory, as evidenced by a CAGR of 3.2% observed between 2018 and 2022.
Key Drivers of Market Growth:
- Rising Incidence of Barrett’s Esophagus and Dysplasia: An increasing prevalence of gastrointestinal disorders, coupled with enhanced awareness and early diagnosis of Barrett’s esophagus with dysplasia, is driving market demand.
- Advancements in Treatment Modalities: Innovations in minimally invasive procedures, endoscopic therapies, and pharmacological interventions are propelling the market forward.
- Supportive Healthcare Infrastructure: Expanding healthcare accessibility and government initiatives focusing on gastrointestinal disease management contribute to the market’s promising outlook.
Future Outlook:
The market is expected to benefit from ongoing research and development efforts aimed at improving treatment efficacy and patient outcomes. Additionally, a growing focus on personalized medicine and targeted therapies is likely to unlock further opportunities for market expansion.
Regional Insights:
North America is anticipated to lead the market, owing to robust healthcare infrastructure and a high prevalence of Barrett’s esophagus. Meanwhile, the Asia-Pacific region is expected to witness rapid growth due to increasing healthcare investments and rising awareness about gastrointestinal health.
As the global healthcare industry continues to prioritize effective management of gastrointestinal conditions, the Barrett’s esophagus with dysplasia treatment market is set to achieve significant milestones. Industry stakeholders are encouraged to leverage the growing demand and focus on innovative solutions to cater to this critical segment.
Key Takeaways from the Market Study:
- From 2018 to 2022, the Barrett’s Esophagus with Dysplasia Treatment market grew at a CAGR of 3.2%.
- The global Barrett’s Esophagus with Dysplasia Treatment market is expected to grow with a 5.3% CAGR from 2023 to 2033.
- As of 2033, the Barrett’s Esophagus with Dysplasia Treatment Market is expected to reach USD 7.54 Million.
- According to the FMI analysis, the hospitals segment accounts for the largest market share.
- North America is expected to possess 40% market share for the Barrett’s Esophagus with Dysplasia Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Barrett’s esophagus with dysplasia treatment,” says an FMI analyst
Enhanced Market Demand: Discover Thorough Trends and Insights in Our Complete Report!
Market Competition:
Key players in the market include companies such as Competition Deep Dive, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., In, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., along with healthcare providers and technology companies among other global players.
- In August 2022, the American College of Gastroenterology has released new guidelines for Barrett’s esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett’s esophagus, and implementing volume criteria for endoscopic therapy centers.
- These guidelines were developed by a team led by Nicholas J. Shaheen, MD, MPH from the University of North Carolina at Chapel Hill, and cover the definition and diagnosis of Barrett’s esophagus, screenings for esophageal adenocarcinoma, surveillance for known Barrett’s esophagus, and medical and endoscopic treatments for Barrett’s esophagus and early neoplasia.
- The authors emphasize that these guidelines should be used as a support for clinical practice and that healthcare providers should take into account patient-specific medical conditions, health status, and preferences to provide patient-centered care.
Key Segments Profiled in the Barrett’s Esophagus with Dysplasia Treatment Industry Survey:
Type:
- Low Grade Dysplasia
- High Grade Dysplasia
Treatment:
- Endoscopic Resection
- Radiofrequency Ablation
- Esophagectomy
- Photodynamic Therapy
- Cryotherapy
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
